As Freenome’s Chief Financial Officer, Linh drives the company’s financial strategy and operational execution as it prepares to scale its commercial footprint.

Linh brings more than two decades of work experience in finance and operations across the diagnostics and Medtech sectors. His domain expertise includes go-to-market strategies for commercialization, scaling high-volume businesses, and driving operational excellence. He served as chief operating officer at Ambry Genetics, where he led organizational transformation efforts that enabled scalability and operational efficiency across the enterprise. Linh also spent over 14 years at Medtronic Diabetes, where he held various leadership positions of increasing responsibilities, including as CFO of its Intensive Insulin Management business unit with oversight across the Americas, EMEA, China and Asia-Pacific.

He began his career in the assurance practice at KPMG, followed by management advisory at PwC. As a certified public accountant, Linh holds a Bachelor of Science in Business Administration and Accounting from California State University, Northridge, and has completed executive coursework at the Wharton School of Business. He was recognized as CFO of the Year by the Los Angeles Times in 2022.